Impact of NMES, Aerobic, and Resistance Exercise on Glycemic Control in Older Adults With Type 2 Diabetes
Launched by CARLOS TAVARES · Feb 26, 2025
Trial Information
Current as of November 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at different ways to help older adults with type 2 diabetes manage their blood sugar levels and improve their quality of life. Researchers want to see how effective neuromuscular electrical stimulation (NMES), aerobic exercise, and resistance exercise are compared to a health education program. They will include participants aged 60 and older, who live in nursing homes or similar settings, and who can understand study instructions. To be eligible, participants must have type 2 diabetes and be able to provide consent. However, those with serious heart problems, certain joint issues, or those on high-risk insulin therapy cannot take part.
Participants in the study will be randomly placed in one of three groups and will receive their assigned intervention for 12 weeks. Throughout the study, researchers will measure fasting glucose levels (a key indicator of diabetes management), monitor how well participants stick to the program, and assess their overall satisfaction and quality of life. This trial is important because it aims to find new ways to help older adults with diabetes, especially those who may not be able to engage in traditional exercise.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with Type 2 Diabetes Mellitus (T2DM).
- • Aged 60 years or older.
- • Sufficient cognitive ability to understand study instructions.
- • Institutionalized in nursing homes or similar settings.
- • Willing and able to provide informed consent.
- Exclusion Criteria:
- • Severe cardiovascular diseases (e.g., heart failure, recent myocardial infarction).
- • Musculoskeletal conditions that prevent exercise participation (e.g., severe arthritis, unhealed fractures).
- • Intensive insulin therapy with high risk of hypoglycemia or significant glycemic control issues.
- • Participation in other clinical trials that could interfere with this study.
About Carlos Tavares
Carlos Tavares is a prominent clinical trial sponsor known for his leadership in advancing innovative healthcare solutions. With a strong focus on improving patient outcomes, Tavares leverages his extensive experience in the pharmaceutical and biotechnology sectors to oversee the development and execution of cutting-edge clinical trials. His commitment to scientific integrity, regulatory compliance, and collaboration with research institutions underscores his dedication to facilitating groundbreaking medical research. Through strategic partnerships and a patient-centric approach, Carlos Tavares aims to accelerate the delivery of safe and effective therapies to the market, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported